TrialPath
Recruiting

An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD

NCT07836647 · Transcend Therapeutics
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD
About this study
This study is evaluating the safety and efficacy of TSND-201 in adults with PTSD. Eligible participants will enter a 4-week Treatment Period where they will be randomized 1:1:1 to receive one of two doses of TSND-201 or placebo, once per week. Following the Treatment Period, participants will enter an 8-week Follow-up Period.
Eligibility criteria
Inclusion Criteria: * Meets DSM-5 criteria for current PTSD diagnosis, with a symptom duration of at least 6 months. * Tried at least one pharmacological treatment for PTSD or trauma-focused psychotherapy. * Proficient in communication (verbal and reading) to complete interviews and written questionnaires. * Free from any other clinically significant illness or disease. Exclusion Criteria: * Primary diagnosis of any other DSM-5 disorder. * Body mass index (BMI) \<18kg/m2 or ≥40 kg/m2. * Unable to refrain from nicotine use for at least 8 hours. * Use of prohibited concomitant medications or therapies. * Current or previous history of clinically significant cardiovascular (including current uncontrolled hypertension) / cerebrovascular conditions.
Study design
Enrollment target: 300 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-09-25
Estimated completion: 2028-02
Last updated: 2026-11-03
Interventions
Drug: TSND-201Drug: Placebo
Primary outcomes
  • • Change from Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Total Severity Score (Up to 12 Weeks)
Sponsor
Transcend Therapeutics · industry
Contacts & investigators
ContactStudy Director · contact · amanda@transcendtherapeutics.com · 650-769-6472
All locations (9)
Mountain View Clinical ResearchRecruiting
Denver, Colorado, United States
Bradenton Research CenterRecruiting
Bradenton, Florida, United States
CNS HealthcareRecruiting
Orlando, Florida, United States
CenExel TampaRecruiting
Tampa, Florida, United States
K2 Medical Research TampaRecruiting
Tampa, Florida, United States
CenExel AtlantaRecruiting
Atlanta, Georgia, United States
CenExel MarltonRecruiting
Marlton, New Jersey, United States
Bio Behavioral HealthRecruiting
Toms River, New Jersey, United States
Cedar Clinical ResearchRecruiting
Draper, Utah, United States
An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD · TrialPath